Celldex's hives drug faces safety questions despite Phase 3 successes

Phase 3positivebarzolvolimabNegative

AI Analysis

Summary

Celldex's barzolvolimab met primary endpoints in two Phase 3 trials for hives treatment, but safety data revealed two life-threatening allergic reaction cases, raising regulatory concerns.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Hit primary endpoint in two Phase 3 trials; however, two life-threatening cases of allergic reaction reported

Importance:7/10

Sentiment:

-0.30

Phase 3 datasafety concernsallergic reactionprimary endpoint met

Related Companies

$CLDX

Read the original article

Published by Endpoints News on September 22, 2026 3:31 PM

Read Original